menu

Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era

close
1.00 credits
60 minutes
Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    Because of advances in the understanding of molecular-driven pathways in non–small cell lung cancer (NSCLC) and the availability of targeted therapies and immunotherapy, the treatment landscape for advanced/metastatic disease has become more complex and continues to evolve. Updated clinical trial data are rapidly becoming available and changes in the treatment paradigm for advanced NSCLC occur on a regular basis.

    In this activity, expert faculty will review treatment options and supporting data for advanced NSCLC patients with and without targetable activating mutations, and outline currently available evidence and guideline recommendations for first- and second-line treatment.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Determine first-line & subsequent tx options, including platinum-based chemo & checkpoint inhibitors, alone or in combination, for pts with advanced/metastatic NSCLC without actionable mutations based on clinical trial data & guideline recommendations
    • Evaluate the use of antiangiogenic agents as subsequent therapy for patients with disease progression after initial therapy
    • Integrate appropriate treatment options for patients with EGFR mutation–positive or ALK rearrangement–positive NSCLC based on available data
    • Evaluate the role of dual blockade of EGFR and VEGFR pathways for the initial treatment of EGFR mutation–positive metastatic NSCLC
  • Target Audience

    This activity is intended for thoracic oncology professionals, medical oncologists, pathologists, pulmonologists, advanced practitioners (nurses and physician assistants), oncology nurses, pharmacists, and other healthcare professionals who manage lung cancer.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

    Karen Reckamp, MS, MD reported a financial interest/relationship or affiliation in the form of Consultant: Amgen, Inc; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Calithera Biosciences Inc; Guardant Health, Inc; Precision Therapeutics, Inc; and Takeda Oncology. Data and Safety Monitoring Board: Genentech, Inc and Tesaro, Inc. Grant/Research Support to Institution (City of Hope): AbbVie; ACEA; Adaptimmune LLC; Boehringer Ingelheim; Bristol-Myers Squibb Company; Genentech, Inc; GlaxoSmithKline; Guardant Health, Inc; Janssen Oncology; Loxo Oncology, Inc; Molecular Partners; Seattle Genetics, Inc; Spectrum Pharmaceuticals, Inc; Takeda Oncology; Xcovery; and Zenopharm.

    Heather Wakelee, MD reported a financial interest/relationship or affiliation in the form of Consultant: AstraZeneca Pharmaceuticals LP; Blueprint Medicines; Daiichi-Sankyo, Inc; Helsinn Therapeutics (US) Inc; and Mirati Therapeutics. Contracted research: ACEA Biosciences; Arrys Therapeutics; AstraZeneca Pharmaceuticals LP/MedImmune; Bristol-Myers Squibb Co; Celgene Corp; Clovis Oncology; Exelixis Inc; Genentech/Roche; Lilly USA; Merck & Co Inc; Novartis Pharmaceuticals Corp; and Pfizer, Inc.

    The planners, managers, and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Annette Quinn, RN, MSN; and Adrienne N. Nedved, PharmD., MPA., BCOP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

  • Accreditation and Credit Designation Statements

    ACCREDITEDCONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 11/11/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit JA4008106-0000-20-025-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    This activity is supported by educational grants from Merck Sharp & Dohme Corp and Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com

  • Terms of Use

    Disclosure of Unlabeled Use   
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
    Recorded on 7/22/2020 and 8/12/2020.

    Method of Participation and Request for Credit: 
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Because of advances in the understanding of molecular-driven pathways in non–small cell lung cancer (NSCLC) and the availability of targeted therapies and immunotherapy, the treatment landscape for advanced/metastatic disease has become more complex and continues to evolve. Updated clinical trial data are rapidly becoming available and changes in the treatment paradigm for advanced NSCLC occur on a regular basis.

    In this activity, expert faculty will review treatment options and supporting data for advanced NSCLC patients with and without targetable activating mutations, and outline currently available evidence and guideline recommendations for first- and second-line treatment.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Determine first-line & subsequent tx options, including platinum-based chemo & checkpoint inhibitors, alone or in combination, for pts with advanced/metastatic NSCLC without actionable mutations based on clinical trial data & guideline recommendations
    • Evaluate the use of antiangiogenic agents as subsequent therapy for patients with disease progression after initial therapy
    • Integrate appropriate treatment options for patients with EGFR mutation–positive or ALK rearrangement–positive NSCLC based on available data
    • Evaluate the role of dual blockade of EGFR and VEGFR pathways for the initial treatment of EGFR mutation–positive metastatic NSCLC
  • Target Audience

    This activity is intended for thoracic oncology professionals, medical oncologists, pathologists, pulmonologists, advanced practitioners (nurses and physician assistants), oncology nurses, pharmacists, and other healthcare professionals who manage lung cancer.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

    Karen Reckamp, MS, MD reported a financial interest/relationship or affiliation in the form of Consultant: Amgen, Inc; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Calithera Biosciences Inc; Guardant Health, Inc; Precision Therapeutics, Inc; and Takeda Oncology. Data and Safety Monitoring Board: Genentech, Inc and Tesaro, Inc. Grant/Research Support to Institution (City of Hope): AbbVie; ACEA; Adaptimmune LLC; Boehringer Ingelheim; Bristol-Myers Squibb Company; Genentech, Inc; GlaxoSmithKline; Guardant Health, Inc; Janssen Oncology; Loxo Oncology, Inc; Molecular Partners; Seattle Genetics, Inc; Spectrum Pharmaceuticals, Inc; Takeda Oncology; Xcovery; and Zenopharm.

    Heather Wakelee, MD reported a financial interest/relationship or affiliation in the form of Consultant: AstraZeneca Pharmaceuticals LP; Blueprint Medicines; Daiichi-Sankyo, Inc; Helsinn Therapeutics (US) Inc; and Mirati Therapeutics. Contracted research: ACEA Biosciences; Arrys Therapeutics; AstraZeneca Pharmaceuticals LP/MedImmune; Bristol-Myers Squibb Co; Celgene Corp; Clovis Oncology; Exelixis Inc; Genentech/Roche; Lilly USA; Merck & Co Inc; Novartis Pharmaceuticals Corp; and Pfizer, Inc.

    The planners, managers, and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Annette Quinn, RN, MSN; and Adrienne N. Nedved, PharmD., MPA., BCOP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

  • Accreditation and Credit Designation Statements

    ACCREDITEDCONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 11/11/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit JA4008106-0000-20-025-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    This activity is supported by educational grants from Merck Sharp & Dohme Corp and Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com

  • Terms of Use

    Disclosure of Unlabeled Use   
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
    Recorded on 7/22/2020 and 8/12/2020.

    Method of Participation and Request for Credit: 
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/3/20